Treatment of high‐risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co‐infusion of T cell‐depleted haematopoietic stem cells and culture‐expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype

Abstract

Summary.A 20-year-old woman with high-risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood CD34+ haematopoietic stem cells and bone-marrowderived mesenchymal stem cells (MSC) from her human leucocyte antigen haplotype-mismatched father after myeloablative conditioning therapy. The patient engrafted rapidly and had no acute or chronic graft-versus-host disease. Since transplantation, the patient has shown an enduring trilineage haematological complete response without any evidence of leukaemia relapse at 31 months. We suggest that MSC can be used effectively for genetically haploidentical haematopoietic stem cell transplantation for acute leukaemia.

Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I–II clinical trial

“…In addition, the dose of MSCs used in our study is similar to the MSC doses in other reports in the literature. [22][23][24][25] The results generated from our study can be used in future for establishment of the acceptable normal range of biological variability between MSC donors.…”

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

“…The first MSC infusion was given at a median of 41 days (range 20-91) after transplantation, donor lymphocyte infusion or cessation of immunosuppression and 16 days after the onset of aGVHD (range 4-31). The median number of MSC transfusion was 2 (range 1-5), the median interval between each MSC application was 7 days (range [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] and the average MSC dose given was 0.9 Â 10 6 per kg body weight (range 0.6-1.1 Â 10 6 per kg body weight) (Table3 and Figure 3). No infusion-related toxicity was observed during or immediately after the administration of MSC.…”

“…5 So far, MSC have been clinically applied to facilitate engraftment in HCT and to prevent and treat aGVHD. [5][6][7][8][9][10][11][12][13][14][15] Materials and methods…”

Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts

“…Finally, relatively large amounts of BM harvest are generally required (50-100 ml) to reach sufficient numbers of hMSCs (from 0.5 to 5 Â 10 6 /kg). 2,[5][6][7][8][9] In order to try and improve the method of expansion of hMSCs in clinical grade conditions, we have added the platelet lysate (PL) commonly produced in the Blood Collection Facility for dermatologic or orthopedic procedures to substitute for the FBS and have performed a close comparison between a selected FBS batch and PL to reach clinically relevant numbers of hMSCs starting from minute amounts of BM cells.…”